Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

[1]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[2]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[3]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[4]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[5]  M. Socinski,et al.  Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. , 2015 .

[6]  L. Sequist,et al.  Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. , 2015 .

[7]  Keunchil Park,et al.  Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). , 2015 .

[8]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[9]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[10]  Yong He.  Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[11]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[12]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[13]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[14]  R. Herbst,et al.  B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer: Current Status and Future Direction , 2014, Cancer journal.

[15]  N. Rizvi,et al.  Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. , 2014 .

[16]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[17]  Vamsidhar Velcheti,et al.  In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.

[18]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[19]  F. Marincola,et al.  The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment , 2013, Journal of Translational Medicine.

[20]  V. Sondak,et al.  12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.

[21]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[22]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[23]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[24]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[25]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[26]  Johan Vansteenkiste,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma , 2009 .

[27]  M. Lederman,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.

[28]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[29]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[31]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[32]  S. Dzik.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[33]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.

[34]  B. Efron.  The Efficiency of Cox's Likelihood Function for Censored Data , 1977 .